Medical tests

Global WholeHealth Partners Corp (OTC:GWHP) Ships Its First Shipment of Over 20,000 Tests to Salud Previa of Tijuana, MX; Salud Previa Has Indicated That It Plans on Purchasing More Than 500,000 Tests Over the Next 12 Months

Retrieved on: 
Thursday, July 8, 2021
Medical specialties, Medicine, Health, Zoonoses, Glycoproteins, Medical tests, Pandemics, Virus, Immunoglobulin G, Antibody, Severe acute respiratory syndrome coronavirus 2, COVID-19

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • Global understands the need to be ahead of the virus to conquer the virus.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Exact Sciences schedules second quarter 2021 earnings call

Retrieved on: 
Thursday, July 8, 2021
Branches of biology, Medicine, Medical specialties, Medical genetics, Medical terminology, Exact Sciences, Medical tests, Cancer screening, Medical diagnosis, Screening

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Pharmed and MyBio Partner to Bring First European Produced and Certified Covid-19 Rapid Antigen Self-test to Pharmacies Across Ireland

Retrieved on: 
Thursday, July 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Medical devices, Infectious diseases, Medicine, Medical tests, Clinical medicine, Health sciences, COVID-19, Occupational safety and health, Public health, Zoonoses, Medical terminology

The MP Biomedicals Covid-19 Rapid Antigen self-test is the only European manufactured, EU Certified Rapid Antigen Self-test, giving results in 15 mins and is 98.72% accurate.

Key Points: 
  • The MP Biomedicals Covid-19 Rapid Antigen self-test is the only European manufactured, EU Certified Rapid Antigen Self-test, giving results in 15 mins and is 98.72% accurate.
  • Peadar Coyle, Business Development Director at Pharmed Ltd said: With an almost 100% distribution network to pharmacies in Ireland we are delighted to be MyBios official distribution partner in Ireland.
  • These Rapid Antigen Self-Tests are an accurate, CE Certified, easy-to-use way to test for Covid-19 and are available in pharmacies nationwide.
  • Their Rapid Sars CoV-2 Antigen Self-Test supplied by MyBio is CE-IVD certified and easy to use.

COVID-19: Doctor's certificates for antigen self-tests now offered online worldwide by DrAnsay.com

Retrieved on: 
Thursday, July 8, 2021
Medicine, Medical tests, Medical terminology, Branches of biology, Clinical medicine, Immunologic tests, Key management, Public key infrastructure, Rapid antigen test, Point-of-care testing, Public key certificate

HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.

Key Points: 
  • HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.
  • To obtain a test certificate online, the user first needs a standard antigen rapid self-test, which he performs himself at any time at any location.
  • Within three minutes he will receive the test certificate in 14 languages as a PDF file 24/7 after verification by an online doctor.
  • Only our efficient online service now quickly and easily allows millions of doctors' certificates of such self-applied tests worldwide," said lawyer and CEO Dr. jur.

COVID-19: Doctor's certificates for antigen self-tests now offered online worldwide by DrAnsay.com

Retrieved on: 
Thursday, July 8, 2021
Medicine, Medical tests, Medical terminology, Branches of biology, Clinical medicine, Immunologic tests, Key management, Public key infrastructure, Rapid antigen test, Point-of-care testing, Public key certificate

HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.

Key Points: 
  • HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.
  • To obtain a test certificate online, the user first needs a standard antigen rapid self-test, which he performs himself at any time at any location.
  • Within three minutes he will receive the test certificate in 14 languages as a PDF file 24/7 after verification by an online doctor.
  • Only our efficient online service now quickly and easily allows millions of doctors' certificates of such self-applied tests worldwide," said lawyer and CEO Dr. jur.

Wren Laboratories Launches First Direct-to-Consumer Saliva COVID-19 PCR Test for Children Ages Five+ and Adults Just in Time for Back-to-School and Work

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Medical tests, Articles, Natural sciences, Molecular biology, Biotechnology, Laboratory techniques, COVID-19 testing, Polymerase chain reaction, Saliva testing, Wren

Wren has been offering one of the nation's most accurate saliva tests since October 2020.

Key Points: 
  • Wren has been offering one of the nation's most accurate saliva tests since October 2020.
  • The Wren PCR test is simple to use, has little room for error, requires just a teaspoon of saliva and does not need any invasive nasal swabbing or similar unpleasant collection approaches.
  • Saliva samples are collected in 2-3 minutes and Wren delivers digital results to the users and schools and workplaces within 24 hours of sample receipt.
  • Several education and community organizations have relied on Wren's PCR Saliva COVID tests throughout the past year including Independence Northwest and Children's Center of Hamden.

Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific

Retrieved on: 
Wednesday, July 7, 2021
Companies, Medical tests, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Industry economics), Fisher Scientific, Economy of the United States, IVD

RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies,today announced its distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.

Key Points: 
  • RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies,today announced its distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.
  • *
    The VITROS QC Solutions will provide customers with a combination of Ortho Clinical Diagnostics controls and Thermo Scientific MAS Quality Controls to bring a complete quality control solution to the laboratory.
  • "Through this agreement with Thermo Fisher Scientific, we can provide laboratories with better solutions, allowing them to maximize their laboratory productivity."
  • To learn more about Ortho's VITROS QC Solutions, please visit: https://www.orthoclinicaldiagnostics.com/en-us/home/contact-us
    Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play, in-vitro diagnostics (IVD) companies dedicated to transforming patient care.

Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific

Retrieved on: 
Wednesday, July 7, 2021
Companies, Medical tests, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Industry economics), Fisher Scientific, Economy of the United States, IVD

RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies,today announced its distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.

Key Points: 
  • RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies,today announced its distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.
  • *
    The VITROS QC Solutions will provide customers with a combination of Ortho Clinical Diagnostics controls and Thermo Scientific MAS Quality Controls to bring a complete quality control solution to the laboratory.
  • "Through this agreement with Thermo Fisher Scientific, we can provide laboratories with better solutions, allowing them to maximize their laboratory productivity."
  • To learn more about Ortho's VITROS QC Solutions, please visit: https://www.orthoclinicaldiagnostics.com/en-us/home/contact-us
    Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play, in-vitro diagnostics (IVD) companies dedicated to transforming patient care.

At $28 Billion, Molecular Diagnostics Revenues Even Surprised Us, Says IVD Market Research Firm

Retrieved on: 
Wednesday, July 7, 2021
Medical tests, IVD, Molecular diagnostics, Life sciences, Biology

Mid 2019, Kalorama Information's report projected the market size (all DNA-based tests, revenues to IVD companies) would reach 10.1 billion in 2021.

Key Points: 
  • Mid 2019, Kalorama Information's report projected the market size (all DNA-based tests, revenues to IVD companies) would reach 10.1 billion in 2021.
  • The finding was made in its latest report, The Worldwide Market for Molecular Diagnostics 10th Edition .
  • The reason is not surprising, says the IVD market research firm.
  • The market figure represents revenues earned by IVD companies selling test products, instruments, reagents and directly related supplies.

Lateral Flow Assays Markets, 2027 by Product (Kits, Readers), Technique (Sandwich, Competitive, Multiplex), Application (Clinical, Food Safety, Drug Development, Veterinary) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Biotechnology, Health, Medical Supplies, Medical devices, Natural sciences, Chemistry, Physical sciences, Laboratory techniques, Medical tests, Immunologic tests, Medical terminology, Chromatography, Lateral flow test, Multiplex, Assay

The "Lateral Flow Assays Market by Product (Kits, Readers), Technique (Sandwich, Competitive, Multiplex), Application (Clinical [Pregnancy, Infectious Diseases], Food Safety, Drug Development, Veterinary), and End User (Hospitals, Home Care) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lateral Flow Assays Market by Product (Kits, Readers), Technique (Sandwich, Competitive, Multiplex), Application (Clinical [Pregnancy, Infectious Diseases], Food Safety, Drug Development, Veterinary), and End User (Hospitals, Home Care) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The lateral flow assays market is expected to grow at a CAGR of 8.8% from 2020 to 2027 to reach $13.85 billion by 2027.
  • In addition, continuous advancements in lateral flow assays are also expected to contribute to the growth of this segment.
  • North America commanded the largest share of the lateral flow assays market in 2020, followed by Europe and Asia-Pacific.